resources

CytoReason, a leader in machine learning for drug discovery and development, and Summit Pharmaceuticals International Corporation (SPI), a wholly-owned subsidiary of Sumitomo Corporation, announced today the signing of a commercial partnership which will see SPI represent CytoReason’s unique immune focused machine learning platform in the Japanese market, the third largest globally.

The alliance will focus on leveraging SPI’s deep knowledge of the Japanese pharmaceutical R&D market, and extensive network of relationships, to highlight CytoReason’s capabilities in understanding and discovering: Disease and drug mode of action (target identification / validation); biomarkers (disease progression and subgroups, patient stratification, companion diagnostics); adverse event profiling; and indication selection and expansion. Financial details of the multi-year collaboration remain undisclosed.

CytoReason has existing collaborations with three of the world’s eight largest pharmaceutical companies. It’s proprietary platform has yielded a range of clinically validated results such as the discovery of novel, blood and tissue-based, pre-treatment biomarkers for anti-TNFa response in Inflammatory Bowel Disease (published in GUT: Gaujoux R et al., PMID: 29618496).

SPI continues promoting innovative technologies in drug discovery and development fields and has had numerous successes in extending such research alliance for their partners.

“CytoReason improves R&D return on investment. We bring increasing accuracy and speed to drug discovery and maximize the value of the data generated across the board, guiding clinical development”, said Dr. Orit Shaked, CytoReason’s Head of Commercial Operations. “Japan represents a global force in the discovery and development of world-class innovative new therapies, and we are delighted to have SPI representing us as we seek to help build upon that reputation.”

“CytoReason is a world-leader in the field of immune-focused machine learning-driven R&D”, said Tetsuya Yamamoto, General Manager of Discovery & Development Division, SPI. “The Japanese market represents a very significant opportunity for companies with proven leading-edge technologies that aim to improve significantly the success rate of drug discovery and development, such as CytoReason. The need for collaborating with such companies is growing all the time, being seen as essential in driving greater effectiveness in turning R&D programs into clinical and commercial successes.”

SPI is a provider of high-quality integrated products and services to pharmaceutical industry, from research equipment and bioresources for drug discovery, pharmaceutical licensing and research alliance support, to manufacturing of APIs, intermediates for pharmaceuticals, generic drugs and biologics. SPI plays a central role in the medical science business line as a group company of Sumitomo Corporation which one of the leading global trading company with 110 locations in 65 countries and 22 locations in Japan with diverse range of products and services.